Podcast: Play in new window | Download (Duration: 39:00 — 33.9MB) | Embed
Subscribe: Apple Podcasts | Spotify | iHeartRadio | Blubrry | TuneIn | Deezer | RSS | More
Dr. Michelle McMurry-Heath, President & CEO of BIO, and John Maraganore, CEO of Alnylam, join Bob Coughlin, President & CEO of MassBio and a leading voice for the biotechnology industry, to discuss the biopharma industry’s response to COVID-19, its efforts to reduce health inequities, and more.
In this episode, the three shed light on the biopharma industry’s incredible efforts in developing potential tests, treatments, and vaccines for COVID-19, and what that means for patients, future drug development research, and the perception of the industry. They also examine the disparity of care for minority populations and how the industry should respond to that need; clinically, socially, and culturally.
To Learn more, visit massbio.org.